Janney Montgomery Scott LLC Has $1.49 Million Stake in Hims & Hers Health, Inc. $HIMS

Janney Montgomery Scott LLC increased its position in Hims & Hers Health, Inc. (NYSE:HIMS) by 126.6% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 71,646 shares of the company’s stock after purchasing an additional 40,023 shares during the quarter. Janney Montgomery Scott LLC’s holdings in Hims & Hers Health were worth $1,487,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of the business. Flagship Harbor Advisors LLC bought a new stake in Hims & Hers Health in the 4th quarter valued at $28,000. Binnacle Investments Inc bought a new position in shares of Hims & Hers Health during the 3rd quarter worth about $28,000. Bogart Wealth LLC lifted its holdings in shares of Hims & Hers Health by 235.8% during the 4th quarter. Bogart Wealth LLC now owns 900 shares of the company’s stock worth $29,000 after acquiring an additional 632 shares during the period. Geneos Wealth Management Inc. acquired a new stake in shares of Hims & Hers Health during the 1st quarter valued at about $30,000. Finally, Greenline Wealth Management LLC acquired a new stake in shares of Hims & Hers Health during the 4th quarter valued at about $36,000. Institutional investors and hedge funds own 63.52% of the company’s stock.

Hims & Hers Health Trading Down 2.8%

Shares of Hims & Hers Health stock opened at $34.45 on Friday. The stock has a market capitalization of $7.97 billion, a P/E ratio of -382.77, a price-to-earnings-growth ratio of 99.77 and a beta of 2.35. The company has a quick ratio of 1.56, a current ratio of 1.69 and a debt-to-equity ratio of 2.18. The company has a 50-day simple moving average of $29.37 and a 200 day simple moving average of $26.39. Hims & Hers Health, Inc. has a 12-month low of $13.74 and a 12-month high of $70.43.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings results on Monday, May 11th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by ($0.44). The firm had revenue of $608.10 million for the quarter, compared to the consensus estimate of $616.84 million. Hims & Hers Health had a negative net margin of 0.56% and a positive return on equity of 6.10%. The company’s revenue for the quarter was up 3.8% on a year-over-year basis. During the same period in the prior year, the business earned $0.20 earnings per share. Research analysts expect that Hims & Hers Health, Inc. will post 0.03 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

HIMS has been the subject of a number of analyst reports. Citigroup raised their price target on shares of Hims & Hers Health from $24.00 to $28.00 and gave the stock a “neutral” rating in a research note on Tuesday, May 12th. Jefferies Financial Group set a $24.50 price objective on Hims & Hers Health in a research note on Tuesday, May 12th. Canaccord Genuity Group increased their target price on Hims & Hers Health from $32.00 to $40.00 and gave the stock a “buy” rating in a report on Wednesday, July 1st. Leerink Partners raised their target price on Hims & Hers Health from $17.50 to $25.00 and gave the stock a “market perform” rating in a research report on Monday, March 16th. Finally, Barclays boosted their price target on Hims & Hers Health from $29.00 to $39.00 and gave the company an “overweight” rating in a research note on Wednesday, June 17th. Four equities research analysts have rated the stock with a Buy rating, ten have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $30.70.

Insider Activity at Hims & Hers Health

In other news, insider Irene Becklund sold 4,490 shares of Hims & Hers Health stock in a transaction that occurred on Wednesday, June 17th. The shares were sold at an average price of $31.50, for a total value of $141,435.00. Following the completion of the transaction, the insider owned 6,790 shares in the company, valued at approximately $213,885. The trade was a 39.80% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, COO Michael Chi sold 14,027 shares of the business’s stock in a transaction that occurred on Wednesday, June 17th. The stock was sold at an average price of $31.50, for a total value of $441,850.50. Following the completion of the transaction, the chief operating officer directly owned 432,124 shares in the company, valued at $13,611,906. The trade was a 3.14% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders have sold 167,161 shares of company stock valued at $5,041,152. Insiders own 11.76% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.